Biocon Biologics secures market access agreements for Yesintek, a biosimilar to Stelara, for treating autoimmune diseases in ...

Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

Biocon Biologics secures multiple market access agreements in the US for its biosimilar, Yesintek, for treating Crohn's ...

Biocon Biologics' biosimilar Yesintek is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis ...

Biocon Biologics Ltd., today announced the Company has secured multiple market access agreements for Yesintek™ ...

Biocon Biologics secures market access for Yesintek in the US driven by demand from national and commercial formularies: Our Bureau, Bengaluru Monday, May 5, 2025, 12:15 Hrs [IST] ...

Clinical studies showed that Yesintek is a biosimilar to Stelara and has similar pharmacokinetic, safety, efficacy and ...

US biotech Biohaven last week received a commitment from Oberland Capital to invest up to $600 million in the company. Also, ...

“Colitis causes inflammation, swelling and ulcers in the large bowel. Everyone experiences it differently,” says Marianne ...